Cancer is the leading cause of disease-related death in Canadian children beyond the newborn period—and even those children who survive cancer will frequently suffer lifelong effects. To improve this situation, Dr. Phillip Lange, Canada Research Chair in Translational Proteogenomics in Pediatric Malignancies, is studying how proteins change in cancer.
He and his research team have discovered specific changes in proteins on cancer cells that hold promise as a new group of anti-cancer targets, and they are investigating the underlying mechanisms. They are also studying how combining genome sequencing with proteome quantification can improve the choice of treatments in precision medicine. Ultimately, they hope to improve cancer therapies by making more treatment choices available and identifying new drug targets.